Market revenue in 2023 | USD 103,870.3 million |
Market revenue in 2030 | USD 229,672.7 million |
Growth rate | 12% (CAGR from 2023 to 2030) |
Largest segment | Health |
Fastest growing segment | Bioinformatics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Health, Food & Agriculture, Natural reseources & Environment, Industrial Processing, Bioinformatics, Others Applications |
Key market players worldwide | AstraZeneca PLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Sanofi SA, Biogen Inc, Abbott Laboratories, Pfizer Inc, Amgen Inc, Novo Nordisk A/S ADR, Merck KGaA, Johnson & Johnson, Novartis AG ADR, Roche Holding AG, Lonza Group Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biotechnology market will help companies and investors design strategic landscapes.
Health was the largest segment with a revenue share of 44.76% in 2023. Horizon Databook has segmented the Germany biotechnology market based on health, food & agriculture, natural reseources & environment, industrial processing, bioinformatics, others applications covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounted for a substantial revenue share in Europe biotechnology market. The close cooperation between research institutes, biotechnology companies, technology parks, and government is a major factor contributing to the market growth in Germany.
Germany is home to major global biotechnology companies, such as Merck KGaA, Eppendorf AG, Sartorius AG, and Cell Genix GmbH, which are expected to witness significant growth in the coming years owing to growing adoption of biotechnology products including biopharmaceuticals.
In December 2020, Merck collaborated with Siemens for the construction of modular plant at its Darmstadt site with the investment of USD 12 million. This development was aimed to digitalize production process for biopharmaceutical products and life sciences tools.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany biotechnology market , including forecasts for subscribers. This country databook contains high-level insights into Germany biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account